CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
NEW YORK, Sept. 13, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) between November 18, 2014 and July 11, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the Central District of California. If you purchased or otherwise acquired CytRx securities between November 18, 2014 and July 11, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/cytrx-corporation.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) and that the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed.
If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/cytrx-corporation.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
